scholarly journals Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer

Oncotarget ◽  
2018 ◽  
Vol 9 (19) ◽  
pp. 15061-15067
Author(s):  
Ariadna Tibau ◽  
Geòrgia Anguera ◽  
Fernando Andrés-Pretel ◽  
Arnoud J. Templeton ◽  
Bostjan Seruga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Systemic Therapy ◽  
Funding Source ◽  
Cooperative Groups

1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer

2015 ◽  
Vol 51 ◽  
pp. S176-S177 ◽  
Author(s):  
G. Anguera ◽  
A. Tibau ◽  
F. Andrés-Pretel ◽  
M. Andrés ◽  
B. Seruga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Studies ◽  
Funding Source ◽  
Cooperative Groups

Primary Systemic Therapy in Operable Breast Cancer

2000 ◽  
Vol 18 (7) ◽  
pp. 1558-1569 ◽  
Author(s):  
Antonio C. Wolff ◽  
Nancy E. Davidson
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Local Control ◽  
Systemic Therapy ◽  
Potential Role ◽  
Operable Breast Cancer ◽  
Primary Systemic Therapy ◽  
Absolute Increase ◽  
Breast Conservation Treatment

PURPOSE: Laboratory studies suggest that primary systemic therapy (PST) could improve control of micrometastatic disease and impact on overall survival (OS). This article examines the rationale for and preclinical and clinical data of PST in operable breast cancer and the potential role of intermediate biomarkers as predictive and/or prognostic factors for response and survival. DESIGN AND METHOD: We conducted an extensive literative review (including MEDLINE) on preclinical studies, single-arm feasibility studies, large randomized single- and multi-institutional trials, and laboratory correlate studies of PST in breast cancer. RESULTS: Small trials in locally advanced disease showed high initial rates of response and local control. Six randomized clinical trials (RCTs) of PST for palpable, operable breast cancer have been reported since 1991 (from 204 to 1,523 patients each). These data clearly show a small but significant (less than 10%) absolute increase in the use of breast-conservation treatment (BCT) with similar rates of local control. Although one study showed better disease-free survival (DFS) and another showed better OS, most studies did not show any survival advantage of primary versus adjuvant systemic therapy. Thus far, pathologic complete response seems to be the best predictor of survival, but clinical response assessment correlates poorly with pathologic response. Pilot studies demonstrated feasibility of procuring tissue at diagnosis and after treatment for assays of potential intermediate biomarkers. Initial data suggest a potential correlation between markers of proliferation and apoptosis and in vivo chemotherapy sensitivity. CONCLUSION: Thus far, RCTs of PST versus standard adjuvant therapy have not shown any clear benefit for DFS or OS in early breast cancer. Ongoing trials should determine if specific subsets of patients at risk would benefit from additional systemic therapy and the potential role of intermediate biomarkers in identifying such women. Although PST results in a small increase in the rate of BCT with similar rates of local control, current PST strategies should not replace standard adjuvant approaches. Rather, they represent an acceptable alternative to women with palpable, operable tumors and an excellent arena for clinical trials.

scholarly journals Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization

2009 ◽  
Vol 119 (3) ◽  
pp. 511-527 ◽  
Author(s):  
Joseph A. Sparano ◽  
Gabriel N. Hortobagyi ◽  
Julie R. Gralow ◽  
Edith A. Perez ◽  
Robert L. Comis
Keyword(s):  
Breast Cancer ◽  
Systemic Therapy ◽  
Research Priorities ◽  
Cooperative Groups

scholarly journals Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials

2009 ◽  
pp. 129 ◽  
Author(s):  
Catherine Abrial ◽  
Durando ◽  
Mouret-Reynier ◽  
Thivat ◽  
Bayet-Robert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Hormonal Therapy ◽  
Adjuvant Hormonal Therapy

scholarly journals Management of Brain and Leptomeningeal Metastases from Breast Cancer

2020 ◽  
Vol 21 (22) ◽  
pp. 8534
Author(s):  
Alessia Pellerino ◽  
Valeria Internò ◽  
Francesca Mo ◽  
Federica Franchino ◽  
Riccardo Soffietti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Systemic Therapy ◽  
Chemotherapeutic Agents ◽  
Leptomeningeal Metastases ◽  
Targeted Agents ◽  
Molecular Subgroups ◽  
Extracranial Disease ◽  
Selection Of Patients ◽  
Selection Of

The management of breast cancer (BC) has rapidly evolved in the last 20 years. The improvement of systemic therapy allows a remarkable control of extracranial disease. However, brain (BM) and leptomeningeal metastases (LM) are frequent complications of advanced BC and represent a challenging issue for clinicians. Some prognostic scales designed for metastatic BC have been employed to select fit patients for adequate therapy and enrollment in clinical trials. Different systemic drugs, such as targeted therapies with either monoclonal antibodies or small tyrosine kinase molecules, or modified chemotherapeutic agents are under investigation. Major aims are to improve the penetration of active drugs through the blood–brain barrier (BBB) or brain–tumor barrier (BTB), and establish the best sequence and timing of radiotherapy and systemic therapy to avoid neurocognitive impairment. Moreover, pharmacologic prevention is a new concept driven by the efficacy of targeted agents on macrometastases from specific molecular subgroups. This review aims to provide an overview of the clinical and molecular factors involved in the selection of patients for local and/or systemic therapy, as well as the results of clinical trials on advanced BC. Moreover, insight on promising therapeutic options and potential directions of future therapeutic targets against BBB and microenvironment are discussed.

The role of systemic therapy for overall survival in breast cancer patients according to molecular substances

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S89
Author(s):  
S. Nikolov ◽  
E. Enchev ◽  
G. Minkov ◽  
M. Galabova ◽  
T. Vlaykova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Breast Cancer Patients ◽  
Molecular Substances

scholarly journals The use of radiation in the elderly

2007 ◽  
Vol 10 (1) ◽  
pp. 1-3 ◽  
Author(s):  
L. A. Schnaper ◽  
K. S. Hughes
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Radiation Therapy ◽  
Randomized Trial ◽  
Postmenopausal Women ◽  
Older Women ◽  
Systemic Therapy ◽  
Elderly Women ◽  
The Elderly

Despite the fact that breast cancer is predominantly a disease of postmenopausal women, there have been no uniform recommendations for both locoregional and systemic therapy for women over 70. Until recently, older women have been excluded from clinical trials. This study is the first randomized trial that addresses the use of radiation therapy following lumpectomy in a favorable cohort of elderly women.

Sign in / Sign up

Export Citation Format

Share Document